Pediatrics and Personalized Medicine
The era of personalized medicine has brought breakthrough advancements in areas like genomic sequencing and gene therapy. Will this reshape the futures of pediatric patients with rare genetic diseases?
That question is at the heart of this planned conversation titled “Pediatrics and Personalized Medicine,” which will begin at 3:45 p.m. on November 13.
This panel discussion will explore what personalized medicine has meant so far for patients, health system administrators, and clinicians who work with pediatric patients — and what it could mean in the future. Participating speakers include:
- Lillian Garvin, who is the Operations Lead for the Center of Precision Medicine at Nicklaus Children’s Hospital;
- Mira Irons, who is the Associate Chief of Genetics and Genomics at Boston Children’s Hospital;
- David Goldstein, who is the CEO of Actio Biosciences, a company that has dedicated itself to the development of medicines for rare genetic diseases with high unmet needs; and
- Julia Vitarello, whose race to save the life of her daughter, Mila, has turned into a mission to forge a new individualized medicine treatment path for all children with fatal genetic diseases.
